AR and prostate carcinoma: ARCC‐4 showed good in vitro potency including low‐nanomolar DC50 (half‐maximal degradation concentrations) value, moderate inhibition on proliferation of prostate cancer cells with better antiproliferative effects on enzalutamide‐resistant AR mutant cells.